Please use this identifier to cite or link to this item: http://hdl.handle.net/1942/8284
Full metadata record
DC FieldValueLanguage
dc.contributor.authorCollette, Laurence-
dc.contributor.authorBUYSE, Marc-
dc.contributor.authorBURZYKOWSKI, Tomasz-
dc.date.accessioned2008-05-20T13:10:06Z-
dc.date.available2008-05-20T13:10:06Z-
dc.date.issued2007-
dc.identifier.citationJOURNAL OF CLINICAL ONCOLOGY, 25(35). p. 5673-5674-
dc.identifier.issn0732-183X-
dc.identifier.urihttp://hdl.handle.net/1942/8284-
dc.language.isoen-
dc.publisherAMER SOC CLINICAL ONCOLOGY-
dc.titleAre prostate-specific antigen changes valid surrogates for survival in hormone-refractory prostate cancer? A meta-analysis is needed!-
dc.typeJournal Contribution-
dc.identifier.epage5674-
dc.identifier.issue35-
dc.identifier.spage5673-
dc.identifier.volume25-
local.format.pages2-
local.bibliographicCitation.jcatA1-
dc.description.notesEuropean Org Res & Treatment Canc Data Ctr, Dept Stat, Brussels, Belgium. Int Inst Drug Dev, Louvain, Belgium. Hasselt Univ, Ctr Stat, Diepenbeek, Belgium.-
local.type.refereedRefereed-
local.type.specifiedLetter-
dc.bibliographicCitation.oldjcatA1-
dc.identifier.doi10.1200/JCO.2007.14.5268-
dc.identifier.isi000253885900035-
item.fulltextNo Fulltext-
item.fullcitationCollette, Laurence; BUYSE, Marc & BURZYKOWSKI, Tomasz (2007) Are prostate-specific antigen changes valid surrogates for survival in hormone-refractory prostate cancer? A meta-analysis is needed!. In: JOURNAL OF CLINICAL ONCOLOGY, 25(35). p. 5673-5674.-
item.accessRightsClosed Access-
item.validationecoom 2009-
item.contributorCollette, Laurence-
item.contributorBUYSE, Marc-
item.contributorBURZYKOWSKI, Tomasz-
crisitem.journal.issn0732-183X-
crisitem.journal.eissn1527-7755-
Appears in Collections:Research publications
Show simple item record

SCOPUSTM   
Citations

11
checked on Sep 2, 2020

WEB OF SCIENCETM
Citations

12
checked on May 8, 2024

Page view(s)

92
checked on May 23, 2023

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.